PACIRA BIOSCIENCES, INC. Selling, General and Administrative Expense
PACIRA BIOSCIENCES, INC. (PCRX) reported Selling, General and Administrative Expense of $91.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $91.81M, a 3.65% increase year-over-year.
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $93.94M, a 8.26% increase year-over-year.
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $101.61M, a 27.63% increase year-over-year.
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $91.80M, a 23.49% increase year-over-year.
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2025 was $368.76M, a 25.39% increase from fiscal 2024.
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2024 was $294.10M, a 9.15% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2023 was $269.44M, a 5.86% increase from fiscal 2022.
- PACIRA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2022 was $254.52M, a 27.68% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $91.81M 10-Q · filed 2026-08-04 | $185.75M 10-Q · filed 2026-08-04 | $287.36M derived: sum of 3 quarters · filed 2026-08-04 | $379.16M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $93.94M 10-Q · filed 2026-04-30 | $195.55M derived: sum of 2 quarters · filed 2026-04-30 | $287.35M derived: sum of 3 quarters · filed 2026-04-30 | $375.93M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $101.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $193.41M derived: sum of 2 quarters · filed 2026-02-26 | $281.98M derived: sum of 3 quarters · filed 2026-08-04 | $368.76M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $91.80M 10-Q · filed 2025-11-06 | $180.38M derived: sum of 2 quarters · filed 2026-08-04 | $267.15M 10-Q · filed 2025-11-06 | $346.76M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $88.58M 10-Q · filed 2026-08-04 | $175.35M 10-Q · filed 2026-08-04 | $254.97M derived: sum of 3 quarters · filed 2026-08-04 | $329.30M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $86.78M 10-Q · filed 2026-04-30 | $166.39M derived: sum of 2 quarters · filed 2026-04-30 | $240.72M derived: sum of 3 quarters · filed 2026-04-30 | $308.85M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2024-12-31 | $79.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $153.95M derived: sum of 2 quarters · filed 2026-02-26 | $222.07M derived: sum of 3 quarters · filed 2026-02-26 | $294.10M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $74.33M 10-Q · filed 2025-11-06 | $142.46M derived: sum of 2 quarters · filed 2025-11-06 | $214.49M 10-Q · filed 2025-11-06 | $280.29M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $68.13M 10-Q · filed 2025-08-05 | $140.15M 10-Q · filed 2025-08-05 | $205.95M derived: sum of 3 quarters · filed 2026-02-26 | $273.90M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $72.03M 10-Q · filed 2025-05-08 | $137.83M derived: sum of 2 quarters · filed 2026-02-26 | $205.77M derived: sum of 3 quarters · filed 2026-02-26 | $270.62M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $65.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $133.75M derived: sum of 2 quarters · filed 2026-02-26 | $198.60M derived: sum of 3 quarters · filed 2026-02-26 | $269.44M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $67.95M 10-Q · filed 2024-11-06 | $132.80M derived: sum of 2 quarters · filed 2024-11-06 | $203.64M 10-Q · filed 2024-11-06 | $267.61M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $64.85M 10-Q · filed 2024-07-30 | $135.69M 10-Q · filed 2024-07-30 | $199.66M derived: sum of 3 quarters · filed 2025-02-27 | $260.95M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $70.84M 10-Q · filed 2024-05-07 | $134.81M derived: sum of 2 quarters · filed 2025-02-27 | $196.10M derived: sum of 3 quarters · filed 2025-02-27 | $261.10M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $63.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $125.25M derived: sum of 2 quarters · filed 2025-02-27 | $190.26M derived: sum of 3 quarters · filed 2025-02-27 | $254.52M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $61.28M 10-Q · filed 2023-11-02 | $126.29M derived: sum of 2 quarters · filed 2023-11-02 | $190.55M 10-Q · filed 2023-11-02 | $242.70M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | $65.00M 10-Q · filed 2023-08-02 | $129.26M 10-Q · filed 2023-08-02 | $181.42M derived: sum of 3 quarters · filed 2024-02-29 | $229.27M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | $64.26M 10-Q · filed 2023-05-03 | $116.41M derived: sum of 2 quarters · filed 2024-02-29 | $164.27M derived: sum of 3 quarters · filed 2024-02-29 | $215.08M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $52.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $100.01M derived: sum of 2 quarters · filed 2024-02-29 | $150.82M derived: sum of 3 quarters · filed 2024-02-29 | $199.34M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $47.86M 10-Q · filed 2022-11-03 | $48.81M 10-Q · filed 2021-11-03 | $98.67M derived: sum of 2 quarters · filed 2022-11-03 | $147.19M 10-Q · filed 2022-11-03 | $148.14M 10-Q · filed 2021-11-03 | $200.02M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $50.81M 10-Q · filed 2022-08-03 | $99.33M 10-Q · filed 2022-08-03 | $152.17M derived: sum of 3 quarters · filed 2023-02-28 | $204.73M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $48.52M 10-Q · filed 2022-05-04 | $101.36M derived: sum of 2 quarters · filed 2023-02-28 | $153.92M derived: sum of 3 quarters · filed 2023-02-28 | $197.26M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $52.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $105.39M derived: sum of 2 quarters · filed 2023-02-28 | $148.74M derived: sum of 3 quarters · filed 2023-02-28 | $193.52M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $52.56M 10-Q · filed 2021-11-03 | $95.90M derived: sum of 2 quarters · filed 2021-11-03 | $140.68M 10-Q · filed 2021-11-03 | $194.91M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $43.34M 10-Q · filed 2021-08-03 | $88.12M 10-Q · filed 2021-08-03 | $142.34M derived: sum of 3 quarters · filed 2022-02-28 | $192.47M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $44.78M 10-Q · filed 2021-05-04 | $99.00M derived: sum of 2 quarters · filed 2022-02-28 | $149.13M derived: sum of 3 quarters · filed 2022-02-28 | $198.26M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $54.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $104.35M derived: sum of 2 quarters · filed 2022-02-28 | $153.48M derived: sum of 3 quarters · filed 2022-02-28 | $200.78M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $50.13M 10-Q · filed 2020-10-30 | $99.25M derived: sum of 2 quarters · filed 2020-10-30 | $146.56M 10-Q · filed 2020-10-30 | $191.21M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-06-30 | $49.13M 10-Q · filed 2020-08-06 | $96.43M 10-Q · filed 2020-08-06 | $141.08M derived: sum of 3 quarters · filed 2021-03-01 | $185.26M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-31 | $47.30M 10-Q · filed 2020-05-07 | $48.52M 10-Q · filed 2019-05-02 | $91.95M derived: sum of 2 quarters · filed 2021-03-01 | $136.13M derived: sum of 3 quarters · filed 2021-03-01 | $180.38M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $44.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $88.83M derived: sum of 2 quarters · filed 2021-03-01 | $133.07M derived: sum of 3 quarters · filed 2021-03-01 | $177.26M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $44.18M 10-Q · filed 2019-11-08 | $88.43M derived: sum of 2 quarters · filed 2019-11-08 | $132.62M 10-Q · filed 2019-11-08 | $171.80M derived: sum of 4 quarters · filed 2020-02-21 | |||
| 2018-06-30 | $44.25M 10-Q · filed 2019-08-08 | $88.44M 10-Q · filed 2019-08-08 | $127.62M derived: sum of 3 quarters · filed 2020-02-21 | $168.26M derived: sum of 4 quarters · filed 2020-02-21 | |||
| 2018-03-31 | $44.19M 10-Q · filed 2019-05-02 | $83.37M derived: sum of 2 quarters · filed 2020-02-21 | $124.01M derived: sum of 3 quarters · filed 2020-02-21 | $163.56M derived: sum of 4 quarters · filed 2020-02-21 | |||
| 2017-12-31 | $39.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $79.82M derived: sum of 2 quarters · filed 2020-02-21 | $119.37M derived: sum of 3 quarters · filed 2020-02-21 | $161.49M 10-K · filed 2020-02-21 | |||
| 2017-09-30 | $40.64M 10-Q · filed 2018-11-01 | $80.20M derived: sum of 2 quarters · filed 2018-11-01 | $122.32M 10-Q · filed 2018-11-01 | $156.99M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-06-30 | $39.55M 10-Q · filed 2018-08-02 | $81.67M 10-Q · filed 2018-08-02 | $116.34M derived: sum of 3 quarters · filed 2019-02-28 | $152.66M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-03-31 | $42.12M 10-Q · filed 2018-05-03 | $76.79M derived: sum of 2 quarters · filed 2019-02-28 | $113.11M derived: sum of 3 quarters · filed 2019-02-28 | $156.78M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | $34.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $70.99M derived: sum of 2 quarters · filed 2019-02-28 | $114.66M derived: sum of 3 quarters · filed 2019-02-28 | $152.61M 10-K · filed 2019-02-28 | |||
| 2016-09-30 | $36.31M 10-Q · filed 2017-11-08 | $79.98M derived: sum of 2 quarters · filed 2017-11-08 | $117.94M 10-Q · filed 2017-11-08 | $155.49M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-06-30 | $43.67M 10-Q · filed 2017-08-02 | $81.63M 10-Q · filed 2017-08-02 | $119.18M derived: sum of 3 quarters · filed 2018-02-28 | $154.49M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-03-31 | $37.96M 10-Q · filed 2017-05-04 | $75.51M derived: sum of 2 quarters · filed 2018-02-28 | $110.82M derived: sum of 3 quarters · filed 2018-02-28 | $145.57M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2015-12-31 | $37.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $72.86M derived: sum of 2 quarters · filed 2018-02-28 | $107.61M derived: sum of 3 quarters · filed 2018-02-28 | $139.04M 10-K · filed 2018-02-28 | |||
| 2015-09-30 | $35.31M 10-Q · filed 2016-11-02 | $70.06M derived: sum of 2 quarters · filed 2016-11-02 | $101.49M 10-Q · filed 2016-11-02 | $208.15M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $34.75M 10-Q · filed 2016-08-04 | $66.18M 10-Q · filed 2016-08-04 | $172.84M derived: sum of 3 quarters · filed 2017-03-01 | $201.06M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $31.43M 10-Q · filed 2016-05-02 | $138.09M derived: sum of 2 quarters · filed 2017-03-01 | $166.31M derived: sum of 3 quarters · filed 2017-03-01 | $191.14M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $106.66M 10-K · filed 2017-03-01 | $134.88M derived: sum of 2 quarters · filed 2017-03-01 | $159.72M derived: sum of 3 quarters · filed 2017-03-01 | $106.66M 10-K · filed 2016-02-25 | |||
| 2014-09-30 | $28.22M 10-Q · filed 2015-10-27 | $53.05M derived: sum of 2 quarters · filed 2015-10-27 | $75.64M 10-Q · filed 2015-10-27 | $95.81M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-06-30 | $24.84M 10-Q · filed 2015-07-30 | $47.43M 10-Q · filed 2015-07-30 | $67.60M derived: sum of 3 quarters · filed 2016-02-25 | $82.92M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-03-31 | $22.59M 10-Q · filed 2015-04-30 | $42.76M derived: sum of 2 quarters · filed 2016-02-25 | $58.08M derived: sum of 3 quarters · filed 2016-02-25 | $72.16M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-12-31 | $20.17M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $35.49M derived: sum of 2 quarters · filed 2016-02-25 | $49.57M derived: sum of 3 quarters · filed 2016-02-25 | $62.51M 10-K · filed 2016-02-25 | |||
| 2013-09-30 | $15.32M 10-Q · filed 2014-10-30 | $29.40M derived: sum of 2 quarters · filed 2014-10-30 | $42.34M 10-Q · filed 2014-10-30 | $55.70M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-06-30 | $14.08M 10-Q · filed 2014-07-31 | $27.02M 10-Q · filed 2014-07-31 | $40.38M derived: sum of 3 quarters · filed 2015-02-24 | $51.76M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-03-31 | $12.94M 10-Q · filed 2014-05-01 | $26.30M derived: sum of 2 quarters · filed 2015-02-24 | $37.68M derived: sum of 3 quarters · filed 2015-02-24 | $48.09M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2012-12-31 | $13.36M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $24.74M derived: sum of 2 quarters · filed 2015-02-24 | $35.15M derived: sum of 3 quarters · filed 2015-02-24 | $46.31M 10-K · filed 2015-02-24 | |||
| 2012-09-30 | $11.38M 10-Q · filed 2013-10-31 | $21.79M derived: sum of 2 quarters · filed 2013-10-31 | $32.94M 10-Q · filed 2013-10-31 | $40.14M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-06-30 | $10.41M 10-Q · filed 2013-08-06 | $21.57M 10-Q · filed 2013-08-06 | $28.76M derived: sum of 3 quarters · filed 2014-02-25 | $33.74M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-03-31 | $11.15M 10-Q · filed 2013-05-08 | $18.35M derived: sum of 2 quarters · filed 2014-02-25 | $23.32M derived: sum of 3 quarters · filed 2014-02-25 | $27.79M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2011-12-31 | $7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $12.17M derived: sum of 2 quarters · filed 2014-02-25 | $16.64M derived: sum of 3 quarters · filed 2014-02-25 | $20.16M 10-K · filed 2014-02-25 | |||
| 2011-09-30 | $4.97M 10-Q · filed 2012-11-01 | $4.99M 10-Q · filed 2011-10-31 | $9.44M derived: sum of 2 quarters · filed 2012-11-01 | $12.96M 10-Q · filed 2012-11-01 | $13.46M 10-Q · filed 2011-10-31 | $15.38M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2011-06-30 | $4.47M 10-Q · filed 2012-08-09 | $4.67M 10-Q · filed 2011-08-11 | $7.99M 10-Q · filed 2012-08-09 | $8.48M 10-Q · filed 2011-08-11 | $10.41M derived: sum of 3 quarters · filed 2013-03-07 | $12.10M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2011-03-31 | $3.52M 10-Q · filed 2012-05-09 | $5.94M derived: sum of 2 quarters · filed 2013-03-07 | $7.64M derived: sum of 3 quarters · filed 2013-03-07 | $8.87M derived: sum of 4 quarters · filed 2013-03-07 | |||
| 2010-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07 | $4.11M derived: sum of 2 quarters · filed 2013-03-07 | $5.35M derived: sum of 3 quarters · filed 2013-03-07 | $6.37M 10-K · filed 2013-03-07 | |||
| 2010-09-30 | $1.69M 10-Q · filed 2011-10-31 | $2.93M derived: sum of 2 quarters · filed 2011-10-31 | $3.95M 10-Q · filed 2011-10-31 | ||||
| 2010-06-30 | $1.24M 10-Q · filed 2011-08-11 | $2.25M 10-Q · filed 2011-08-11 | |||||
| 2009-12-31 | $5.02M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |